Focus on rare diseases projects

chiffre 1

Commercially-viable model

chiffre 2

Potential to translate into clinics within 2-4 years

chiffre 3

Technology-agnostic

chiffre 4

we

develop
projects

and we

support
founders

to

create
champions

how we help founders

domaines d'activité strategy, finance, ressources humaines, marketing, r et d, juridique

• Business development
• Competitive analysis
• Market studies

• Business plan and budget
• Accounting and tax credit
• Fundraising

• Headhunt of key profiles
• Program « Coach the founders »
• HR regular consulting

• Name and branding strategy
• Visual identity
• Website

• POC consolidation
• Non-clinical development  
• CMC
• Regulatory & Clinical strategy

• Startup incorporation and administration
• Contract management
• IP protection and strategy

how we help founders

logo représentant le domaine Strategy

STRATEGY

•Business development
•Competitive analysis
•Market studies
Logo représentant le domaine Finances

FINANCE

•Business plan and budget
•Accounting and tax credit
•Fundraising
Logo représentant le domaine Ressource Humaine

HUMAN RESSOURCES

•Headhunt of key profiles
•Program « Coach the founders »
•HR regular consulting
Logo représentant le domaine Marketing

MARKETING

•Name and branding strategy
•Visual identity
•Website
Logo représentant le domaine Science

R&D

•POC consolidation
•Non-clinical dev.
•CMC
•Regulatory & Clinical strategy
Logo représentant le domaine Juridique

LEGAL & IP

•Startup incorporation and administration
•Contract management
•IP protection and strategy

AMPLEIA INVESTMENT SELECTION PROCESS

hundreds

research projects in rare
diseases monitored

Create the widest and most diversified portfolio of promising projects for rare diseases

30-50

mature projects followed-up

Scientific maturity for preclinical translation
• Research-grade PoC in vitro, in cellular models and in vivo.
• Preliminary non-toxicity elements are a plus.
• Product optimization on-going or completed (incl. Construct/design, formulation, RoA…)
• IP-protected construct

Potential for economically-viable commercialization
• Eligible patient pool i.e. incidence, prevalence, est. inclusion criteria, competition
• Technology modality and pricing background
• Curative potential

Assessments of incubation and exit options for Ampleia
• Budget and resources allocation assessment
• Single-asset program vs. Ubiquitous technology-platform
• Appetite assessment from pharma for strategic partnering and VCs for syndication
• Timing for exit (i.e. end of incubation)

20

due-diligences

We will perform due-diligence across the following expertise:

Intellectual Property          Preclinical development plan

Scientific & Medical needs         Human Resources

investment committee

Presentation to the investment committee composed of experts and executives from biopharma industry, therapeutic development and VCs

4 NEW
projects

INCUBATED
EACH YEAR

hundreds

research projects in rare
diseases monitored

Create the widest and most diversified portfolio of promising projects for rare diseases

30-50

mature projects followed-up

Scientific maturity for preclinical translation
• Research-grade PoC in vitro, in cellular models and in vivo.
• Preliminary non-toxicity elements are a plus.
• Product optimization on-going or completed (incl. Construct/design, formulation, RoA…)
• IP-protected construct

Potential for economically-viable commercialization
• Eligible patient pool i.e. incidence, prevalence, est. inclusion criteria, competition
• Technology modality and pricing background
• Curative potential

Assessments of incubation and exit options for Ampleia
• Budget and resources allocation assessment
• Single-asset program vs. Ubiquitous technology-platform
• Appetite assessment from pharma for strategic partnering and VCs for syndication
• Timing for exit (i.e. end of incubation)

20

due-diligences

We will perform due-diligence across the following expertise:

Intellectual Property          Preclinical development plan

Scientific & Medical needs         Human Resources

investment committee

Presentation to the investment committee composed of experts and executives from biopharma industry, therapeutic development and VCs

4 NEW
projects

INCUBATED
EACH YEAR

hundreds

research projects in rare
diseases monitored

Create the widest and most diversified portfolio of promising projects for rare diseases

30-50

mature projects followed-up

Scientific maturity for preclinical translation
• Research-grade PoC in vitro, in cellular models and in vivo.
• Preliminary non-toxicity elements are a plus.
• Product optimization on-going or completed (incl. Construct/design, formulation, RoA…)
• IP-protected construct

Potential for economically-viable commercialization
• Eligible patient pool i.e. incidence, prevalence, est. inclusion criteria, competition
• Technology modality and pricing background
• Curative potential

Assessments of incubation and exit options for Ampleia
• Budget and resources allocation assessment
• Single-asset program vs. Ubiquitous technology-platform
• Appetite assessment from pharma for strategic partnering and VCs for syndication
• Timing for exit (i.e. end of incubation)

20

due-diligences

We will perform due-diligence across the following expertise:

Intellectual Property          Preclinical development plan

Scientific & Medical needs         Human Resources

investment committee

Presentation to the investment committee composed of experts and executives from biopharma industry, therapeutic development and VCs

4 NEW
projects

INCUBATED
EACH YEAR